Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas

Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomasIndoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas, Published online: 20 March 2018; doi:10.1038/s41379-018-0039-1Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas

Source: Modern Pathology - March 20, 2018 Category: Pathology Authors: Anne Mills Sara Zadeh Emily Sloan Zachary Chinn Susan C. Modesitt Kari L. Ring Source Type: research